It’s only fair to share… Deulumateperone CAS 2102683-75-8 MF C24H262H2FN3O MW 395.5 g/mol 4-[(10R,15S)-3,3-dideuterio-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]-1-(4-fluorophenyl)butan-1-one antipsychotic, ITI-1284, ITI 1284, NBA7J58PPP, Deulumateperone (INNTooltip International Nonproprietary Name; developmental code name ITI-1284) is an experimental antipsychotic of the pyridopyrroloquinoxaline and butyrophenone families as well as a deuterated analogue of lumateperone which is under development as a sublingually administered orally disintegrating tablet (ODT) for the treatment of psychotic disorders, agitation, and generalized anxiety disorder.[2][3][4][1] No recent development has been reported for treatment …
Tag «anax labs»
Daraxonrasib
It’s only fair to share… Daraxonrasib CAS 2765081-21-6 MFC44H58N8O5S MW811.0 g/mol trans-(1S,2S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3-pyridinyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide Kirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, RMC-6236, RMC 6236, B6T47Y2UAP, RAS-IN-2, Daraxonrasib (formerly RMC-6236) is an investigational, orally administered “molecular glue” RAS inhibitor developed by Revolution Medicines for treating advanced solid tumors with RAS mutations, particularly metastatic pancreatic cancer. April 2026 Phase 3 …